|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proximagen Neuroscience plc (AIM : PRX) is a publicly traded biotechnology company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system.
The Company's strong balance sheet makes Proximagen one of the best capitalised biotechnology companies in the small and mid cap European biotech sector.
Proximagen is developing a broad pipeline of drug candidate programmes and has plans for substantial future growth through a strategy of acquisition and consolidation in its preferred therapeutic area of the central nervous system.
Proximagen's Corporate Objectives:
- Expanding our pipeline within CNS through in-house discovery, acquisition, in-licencing and partnering, thus building quality and critical mass in research and development.
- Offer a rewarding corporate culture to motivate and retain our employees.
- Retention of strong downstream participation in all commercialised programs.
Proximagen is committed to the best interests of patients, the medical profession, our employees and our communities, and to seeking significant returns for our shareholders, based on the continuous pursuit of scientific and operational excellence.
|
|
|
|
|
|
|
